#CNBR_Open Seminar

Targeting Ferroptosis for the Treatment of Neurodegenerative Diseases
Dr. Marcus Conrad
12th Oct. 2021
17.00 - 18.30 МSК
16:00 - 17:30 CET
10:00 - 11:30 EST
CNBR Skoltech, (offline, E-R2-2026)
ZOOM (online)
The recognition of distinct regulated cell death pathways presents tantalizing possibilities for gaining control over life and death decisions made by cells in order to prevent diseases and to aid in tissue regeneration.

While apoptosis has been the center of attention for decades, research into the cell death mechanisms has unearthed regulatory processes and signaling pathways for novel, regulated necrotic cell death routines.

Among these, ferroptosis stands out as it emerges to be the root cause for a myriad of diseases and in particular neurodegeneration. Ferroptosis is a metabolic form of cell death and is marked by iron-dependent lipid peroxidation and rupturing of cellular membranes.

Since the ferroptosis pathway offers several tractable nodes for pharmacological intervention, the identification and preclinical development of ferroptosis modulating drugs harbor the great potential to be developed as powerful drugs to combat insofar incurable diseases including dementia and other degenerative diseases.

In the #CNBR_Open Seminar with Dr. Marcus Conrad we will discuss the basic principles of ferroptosis and learn how to discover new players and cellular processes determining the cell's sensitivity towards ferroptosis with the ultimate goal to develop novel and targeted therapies to prevent ferroptosis-related diseases.
To registration
About Speaker
Marcus Conrad
Dr. Marcus Conrad is director of the Institute of Metabolism and Cell Death at the Helmholtz Zentrum München in the field of metabolic cell death signaling and drug discovery.

His research interests lie in the field of the study of redox-regulated cell fate decisions.

Dr. Conrad generated the first mouse models with conditional knockout of the main mammalian redox-enzymes, allowing him to discover a previously uncharacterized cell death modality, now known as ferroptosis.

His current work is focused on studying the molecular mechanisms of ferroptosis as the basis for the development of novel therapies to combat difficult-to-treat diseases such as neurodegeneration and cancer.

In addition, he is developing novel ferroptosis modulating drugs, of which some have entered preclinical development for the treatment of ischemia-reperfusion-related tissue injuries, such as organ transplantation and ischemic stroke.

He has published more than 130 scientific articles and book chapters, which have received more than 18000 citations meanwhile.

Dr. Marcus Conrad holds several patents and is co-founder and shareholder of ROSCUE Therapeutics GmbH.
17:00 - 18:30 МСК
sharing knowledge in neuroscience and neurotechnology
Subscribe for CNBR_Open events
Skolkovo Institute of Science and Technology

Bolshoy Boulevard 30, bld. 1
Moscow, Russia 121205

How to get there:


Please contact us in case of any questions related to this event:
+7 977 283 16 96 (Telegram, Whatsapp)